On Mar 10, 2022 Puma Biotechnology closed a Post-IPO Equity round and raised $10,000,000 from Alan H. Auerbach, Athyrium Capital Management LP, featuring lead investors .
About the company: Puma Biotechnology is located at United States, North America.
“Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the acquisition, development and commercialization of novel therapeutics for the treatment of cancer. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
Neratinib, oral was approved by the U.S. Food and Drug Administration (FDA) in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Union in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy.
Pumas licensing partners have also received marketing authorization to commercialize NERLYNX in Canada, Israel, and several countries in Europe, Greater China, South America and Southeast Asia.
NERLYNX® is a registered trademark of Puma Biotechnology, Inc.
Puma Biotechnology was founded by Alan Auerbach in 2010 and is headquartered in Los Angeles, California. Mr. Auerbach previously founded and served as Chief Executive Officer and President of Cougar Biotechnology, Inc., a company dedicated to in-licensing and developing drugs for the treatment of cancer. Cougar was acquired by Johnson & Johnson in July 2009 for approximately $1 billion.
Additional information may be found at www.pumabiotechnology.com.”
Company website: http://www.pumabiotechnology.com
